Point72 Asia Singapore Pte. Ltd. Purchases Shares of 45,520 Ikena Oncology, Inc. (NASDAQ:IKNA)

Point72 Asia Singapore Pte. Ltd. acquired a new position in Ikena Oncology, Inc. (NASDAQ:IKNA) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 45,520 shares of the company’s stock, valued at approximately $75,000. Point72 Asia Singapore Pte. Ltd. owned about 0.09% of Ikena Oncology as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. BVF Inc. IL grew its holdings in Ikena Oncology by 50.5% in the fourth quarter. BVF Inc. IL now owns 4,769,164 shares of the company’s stock worth $9,395,000 after purchasing an additional 1,600,000 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its position in Ikena Oncology by 813.7% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 513,440 shares of the company’s stock valued at $729,000 after buying an additional 457,245 shares in the last quarter. Acadian Asset Management LLC raised its stake in Ikena Oncology by 1,201.8% in the first quarter. Acadian Asset Management LLC now owns 282,782 shares of the company’s stock valued at $400,000 after buying an additional 261,060 shares during the last quarter. Vestal Point Capital LP acquired a new stake in Ikena Oncology in the fourth quarter worth about $636,000. Finally, BBR Partners LLC purchased a new stake in shares of Ikena Oncology during the second quarter worth about $33,000. Institutional investors own 75.00% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $4.00 target price on shares of Ikena Oncology in a research note on Monday, August 12th.

Ikena Oncology Price Performance

NASDAQ IKNA opened at $1.73 on Monday. The company has a market cap of $83.49 million, a price-to-earnings ratio of -1.09 and a beta of 0.48. The stock’s fifty day moving average price is $1.69 and its 200 day moving average price is $1.57. Ikena Oncology, Inc. has a 1 year low of $1.02 and a 1 year high of $4.66.

Ikena Oncology (NASDAQ:IKNA) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.04. Research analysts expect that Ikena Oncology, Inc. will post -1.03 earnings per share for the current year.

About Ikena Oncology

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.